Quantcast
Last updated on April 23, 2014 at 13:11 EDT

Latest Uric acid Stories

2012-05-01 13:56:11

Teens with high levels of uric acid appear to be at increased risk for high blood pressure, according to results of research from scientists at Johns Hopkins Children´s Center. Although the findings do not establish a cause-and-effect link between uric acid and high blood pressure, they point to uric acid as one potential mechanism, or at least a biomarker, of disease, the researchers report in the April issue of the journal Hypertension. Analyzing more than 6,000 medical records...

2012-05-01 11:01:13

Contrary to current belief, a new study finds that patients with a history of diabetes are not one of the most at risk for contrast induced nephrotoxicity. Instead, the study found that patients with a history of renal disease, hypertension and/or heart disease are more likely to suffer from renal insufficiency, putting them at greater risk for contrast induced nephrotoxicity. The study, done at Northwestern Memorial Hospital-Northwestern University in Chicago, included 2,404 patients. All...

2012-04-24 06:26:49

PHILADELPHIA and LONDON, April 24, 2012 /PRNewswire/ -- In just over a year, Gout Study on Facebook has exceeded 50,000 'likes' making it the largest online gout community globally. With nearly a quarter of its members from outside the U.S., its rapid rise in popularity demonstrates a keen interest in exchanging information and sharing experiences among those afflicted by this painful condition. Once thought to be a disease that affected those living a life of indulgence; fine food and...

2012-04-16 02:28:45

ISELIN, N.J., April 16, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today reported financial results for the first quarter ended March 31, 2012. The Company recorded a net loss of $0.6 million, or $(0.01) per share, for the first quarter 2012 compared to a net loss of $0.6 million, or $(0.01) per share, in the first quarter 2011. The Company is currently conducting a clinical trial at the Duke Clinical Research Unit to evaluate levotofisopam as a treatment for gout. As of...

2012-04-05 10:24:46

ISELIN, N.J., April 5, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today provided an update on the ongoing clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a proof-of-concept trial is being conducted at the Duke Clinical Research Unit of Duke University and the principal investigator is John Sundy, MD, PhD an expert in the treatment of gout. The trial is designed to assess the safety and efficacy of...

2012-03-05 07:00:00

EAST BRUNSWICK, N.J., March 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that KRYSTEXXA®(pegloticase) is now available in the European Union to healthcare professionals and their patients suffering from refractory chronic gout (RCG) through a Named Patient Programme, which is sponsored by its wholly-owned subsidiary, Savient Pharma Ireland Limited, and managed by Idis Limited (Idis). RCG is a difficult-to-treat form of gout and currently there are...

2012-01-24 11:11:33

A daily dose of skimmed milk, enriched with two components found in dairy products, may help to curb the frequency of painful gout flare-ups, indicates research published online in the Annals of the Rheumatic Diseases. Previous long term research has shown that the risk of gout is greater among those whose diet is low on dairy products. And experimental studies indicate that certain components of dairy products, particularly glycomacropeptide (GMP) and G600 milk fat extract (G600), seem...

2012-01-10 15:15:00

ISELIN, N.J., Jan. 10, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) announced today the dosing of the first patients in the US using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a proof-of-concept trial is being conducted at the Duke Clinical Research Unit of Duke University and the principal investigator is John Sundy, MD, PhD an expert in the treatment of gout. The trial is designed to assess the safety and...

2012-01-06 07:00:00

EAST BRUNSWICK, N.J., Jan. 6, 2012 /PRNewswire/ --Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that a product-specific billing code, or permanent J-code, for KRYSTEXXA® (pegloticase) became available on January 1, 2012. The new J-code, J2507, was assigned by the Centers for Medicare and Medicaid Services (CMS) and will help simplify the billing and reimbursement process for prescribers of KRYSTEXXA, the first and only U.S. Food and Drug Administration (FDA)...

2012-01-05 12:04:52

Drug appears to be well tolerated by patients A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial–the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares–show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events...